Physician profile
Philipp A Sack
NPI 1790974863
$1,713.80
in general payments reported to CMS, 2019-2025
16 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $390 · 2021: $340 · 2022: $55.93 · 2023: $195 · 2024: $187 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488 · Education: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.65 |
| Education | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $332.63 | 2019-2025 | Rexulti |
| Allergan, INC. | $294.54 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.66 | 2021-2025 | Caplyta |
| Abbvie INC. | $145.07 | 2021-2022 | |
| Alkermes, INC. | $139.26 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $124.44 | 2021 | |
| Lundbeck LLC | $111.08 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $105.41 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $60.16 | 2019-2023 | Uzedy |
| Bausch Health US, LLC | $53.87 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $51.08 | 2023-2024 | Qelbree, Qelbree |
| Neuronetics, INC. | $44.51 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.05 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $24.86 | 2025 | |
| Vertical Pharmaceuticals, LLC | $15.95 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.23 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philipp Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.